dermavant®

CORPORATE FACT SHEET
Issued August 2020

Dermavant is committed to fostering unprecedented change and unparalleled impact in immuno-dermatology.

We're doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.

Dermavant at-a-glance

- Clinical-stage biopharmaceutical company
- Founded September 2015
- A subsidiary of Roivant Sciences
- U.S. operations in Long Beach, California and Raleigh-Durham, North Carolina

About Dermavant

A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage bio-pharmaceutical company focused on developing products that represent new treatment categories and address some of the greatest challenges providers and patients encounter.

The company's robust medical dermatology pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immune-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne.

Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a novel therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of plaque psoriasis and atopic dermatitis, which affect approximately 8 million and 27 million people in the United States, respectively.

Management team

Todd Zavodnick
Chief Executive Officer

Philip M. Brown, MD, JD
Chief Medical Officer

Chris Chapman
Chief Commercial Officer

David Rubenstein, MD, PhD
Chief Scientific Officer

Christopher Van Tuyl, JD
General Counsel

Investor Relations Key Contact
Kara Stancell · 520-858-0027 · kara.stancell@dermavant.com

To learn more,
visit **www.Dermavant.com**.

Dermavant has five product candidates addressing:

Psoriasis · Atopic Dermatitis · Vitiligo · Hyperhidrosis · Acne

PRODUCT CANDIDATE	INDICATION	STAGE OF DEVELOPMENT
		Preclinical · Phase 1 · Phase 2 · Phase 3
Tapinarof (DMVT-505) A topical, therapeutic AhR modulating agent (TAMA), inhibiting several proinflammatory factors	Psoriasis	
	Atopic Dermatitis	
Cerdulatinib (DMVT-502) A topical dual JAK/Syk inhibitor	Vitiligo	
	Atopic Dermatitis	
Oxybutynin/Pilocarpine (DMVT-504) An oral combination of an immediate-release muscarinic antagonist with a delayed-release muscarinic agonist	Primary Focal Hyperhidrosis	
DMVT-503 A novel mechanism of action for the topical treatment of acne vulgaris	Acne Vulgaris	
Lotamilast (DMVT-501) A highly selective topical PDE4 inhibitor	Atopic Dermatitis	

Excludes certain Asian territories

Key U.S. market data as of 2019

Psoriasis: 8M patients[1]

- $12.0B sales[2]
- $19.3B by 2026[2]
- Topical treatments are ~80% of U.S. Rxs[3,4]

Atopic dermatitis: 27M patients[5]

- $1.8B sales[2]
- $5.7B by 2026[2]
- Topical treatments are ~97% of U.S. Rxs[3,4]

Vitiligo: 2.4M patients[6]

- No FDA-approved therapies

Hyperhidrosis: 15.3M patients[7]

- No FDA-approved systemic treatments

References: 1. National Psoriasis Foundation. **2.** Evaluate Pharma. **3.** IQVIA NDTI 2020. **4.** Symphony Prescriber Source 2020. **5.** National Eczema Association. **6.** Rose & Mackay, US Census. **7.** Doolittle, J. et al. Arch Dermatol Res, 2016, 308:743-749; US Census.

Main Phone Number: 919-767-3277

Company locations:

Long Beach, California Office
Dermavant Sciences, Inc.
3780 Kilroy Airport Way, Suite 250
Long Beach, CA 90806

Raleigh-Durham, North Carolina Office
Dermavant Sciences, Inc.
3300 Paramount Parkway, Suite 150
Morrisville, NC 27560

Basel, Switzerland Office
Dermavant Sciences GmbH
Viaduktstrasse 8
4051 Basel